Code | 3372D | ||||||||||
MA number | 44/0010/20-S | ||||||||||
Product Form: | tbl flm 30x100 mg (fľ.HDPE) | ||||||||||
MA Status: | R - Valid Marketing Authorisation | ||||||||||
Type of procedure: | Decentralised | ||||||||||
MAH, country: | MSN Labs Europe Limited, Malta | ||||||||||
Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
ATC: |
|
||||||||||
Shelf life: | 30 | ||||||||||
Route of admin.: | Oral use |
Prescription Status: | Medicinal product subject to restricted medical prescription. |
Legal basis: | Article 10(1) generic application |
MA issued: | 27.01.2020 |
Validity: | 27.01.2025 |
MA renewed: | Renewal application submitted |
Pediatric indication: | Yes |
Pediatric posology: | Yes |
Pediatric warnings: | Yes |
SPC: | SPC_Dasatinib MSN 100 mg_04.2024.pdf |
PIL: | PIL_Dasatinib MSN 100 mg_04.2024.pdf |
Safety feature | Yes |
Data update: | 04.12.2023 |